鼻内肉毒杆菌毒素A喷雾治疗鼻炎的安全性与有效性Ⅰ期研究
该Ⅰ期单组开放非随机试验纳入15例鼻炎患者,14例接受鼻内肉毒杆菌毒素A喷雾(每鼻孔20单位,共40单位)治疗,未报告严重或相关不良事件。从第0周到第12周,总鼻症状评分(TNSS)和视觉模拟量表(VAS)均出现显著下降,但研究缺乏盲法、替代剂量及安慰剂或活性对照。
要点
- 鼻内肉毒杆菌毒素A喷雾在Ⅰ期试验中未报告严重或相关不良事件。
- TNSS和VAS从第0周到第12周均显著降低。
- 疗效需谨慎解读:无盲法、无安慰剂或活性对照。
核心结论
- 鼻内肉毒杆菌毒素A喷雾在Ⅰ期试验中显示安全,未出现显著不良事件,并降低了队列的TNSS和VAS。
- 因缺乏盲法、替代剂量及安慰剂或公认活性治疗对照,疗效需结合此背景解读。
研究设计与样本
- 单组开放标签非随机Ⅰ期临床试验。
- 15例参与者入组,14例接受治疗;鼻炎和非过敏性鼻炎经正式检查及总IgE和放射过敏原吸附试验(RAST)确认。
主要发现
- 未报告严重不良事件或相关不良事件。
- 从第0周到第12周,TNSS出现统计学和临床显著降低,VAS出现统计学显著降低。
- PNIF在第0周和第4周测量,并使用最小临床重要差异(MCID)证明TNSS评分的临床显著变化。
关键数值与推荐
- 参与者接受40单位肉毒杆菌毒素A,经鼻内局部给药,每鼻孔20单位,使用LMA MAD鼻内黏膜雾化装置。
- TNSS和VAS在第0、2、4和12周评估;PNIF在第0和4周测量。
临床怎么用
- 该安全数据可支持未来研究试验的开展,但当前疗效证据受限于无盲法、无对照的设计。
局限性
- 无盲法、无替代剂量、未与安慰剂或公认活性治疗选项比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Botulinum toxin type A is a potent neurotoxin and was first approved for use in 1989; since there has been a surge in its uses. The latest international trend is the unapproved use of botulinum toxin for allergic and nonallergic rhinitis, being advertised as "Haytox." METHODS: A single-group open-label non-randomized Phase 1 clinical trial was completed. Rhinitis and nonallergic rhinitis were confirmed via formalized examination and testing with total IgE and radioallergosorbent test (RAST). Participants received 40 units of botulinum toxin type A, administered topically intranasally, 20 units per nostril, using the LMA MAD Nasal Intranasal Mucosal Atomization Device. Safety of the intervention was assessed with adverse event tracking logs. Symptom scores were used to assess symptom reduction, including total nasal symptom score (TNSS), visual analog scale (VAS) measurements at Weeks 0, 2, 4, and 12. In addition, peak nasal inspiratory flow (PNIF) was measured at Weeks 0 and 4, with the minimum clinically important difference (MCID) being used to demonstrate any clinically significant change in the TNSS score. RESULTS: A TOTAL OF: 15 participants enrolled, of which 14 participants received treatment, with no serious adverse or related adverse events reported. There was a statistically and clinically significant reduction in TNSS and a statistically significant reduction in VAS from Weeks 0 to 12. CONCLUSION: In this Phase 1 trial, topical application of botulinum toxin via spray was shown to be safe, without any significant adverse events. It reduced the TNSS and VAS across the cohort. However, the treatment efficacy should be taken in context as there was no blinding, alternative dosing, or comparison against placebo or recognized active treatment options. This safety data should embolden future research trials. TRIAL REGISTRATION: TGA number: CT-2024-CTN-02905-1; ANZCTR number: ACTRN12624000772549.
引用
- Bates J, Liaw J, Girling K, et al. A Phase 1 Research Trial to Evaluate the Safety and Effectiveness of Intranasal Botulinum Toxin Type A Spray for Patients With Rhinitis. Int Forum Allergy Rhinol. 2025. PMID: 41139237. doi:10.1002/alr.70058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。